Clinical Trials
15 trialsNCT04542382 2025-03-30
BCRPmarker
University of California, San Francisco
Phase 1 Completed
NCT05924152 2024-03-13
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
Mirati Therapeutics Inc.
Phase 1 Completed
NCT01428635 2023-09-26
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT01772420 2023-07-27
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Albert Einstein College of Medicine
Phase 2 Completed
NCT01168921 2023-03-23
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT02323178 2021-04-20
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
Groupe Francophone des Myelodysplasies
Phase 1/2 Completed
NCT01893372 2020-02-18
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01890746 2019-09-11
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Phase 2 Completed
NCT01286675 2019-03-01
Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
Dana-Farber Cancer Institute
Phase EARLY_PHASE1 Completed
NCT01610180 2018-07-16
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Fondazione Progetto Ematologia
Phase 2 Completed
NCT00358540 2017-11-13
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
GlaxoSmithKline
Phase 1 Completed
NCT01440374 2017-06-05
ASPIRE
Novartis
Phase 2 Completed
NCT00102726 2017-03-23
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
GlaxoSmithKline
Phase 2 Completed
NCT01488565 2016-02-15
Aza-E
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed